Medicare GLP-1 Bridge Just Launched: $50/Month Wegovy and Zepbound — Who Qualifies
As of July 1, 2026, Medicare beneficiaries can access GLP-1 weight loss drugs for a fixed $50 monthly copay through the new Medicare GLP-1 Bridge program. This is the first time Medicare has covered drugs prescribed solely for obesity. Here's who qualifies, what's covered, and how to enroll.
Key Takeaways
- The Medicare GLP-1 Bridge launched July 1, 2026 and runs through December 31, 2027. It provides eligible Medicare Part D beneficiaries access to GLP-1 weight loss drugs for a fixed $50 monthly copay.
- Covered medications: Wegovy (semaglutide injection and tablets), Zepbound (tirzepatide KwikPen), and Foundayo (orforglipron) — when prescribed for weight reduction.
- Eligibility requires Medicare Part D enrollment PLUS meeting BMI criteria: BMI 35+ (no additional conditions needed), BMI 30+ with heart failure, uncontrolled hypertension, or chronic kidney disease, or BMI 27+ with pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease.
- This is the first time Medicare has helped pay for drugs prescribed solely for obesity — a historic shift in coverage policy.
- The $50 copay does NOT count toward your deductible or out-of-pocket cap, and Extra Help benefits cannot be applied to Bridge claims.
- New data confirms GLP-1 drugs work equally well in seniors: a study of 358 adults 65+ showed 15.5% average weight loss on semaglutide, nearly identical to younger adults (15.6%).
This content is for informational purposes only and is not medical or legal advice. Full disclaimer
What the Medicare GLP-1 Bridge Is — And Why It Matters
The Medicare GLP-1 Bridge is a short-term demonstration program run by the Centers for Medicare & Medicaid Services (CMS) that provides eligible Medicare Part D beneficiaries access to GLP-1 weight loss medications for a fixed $50 monthly copay.
Program dates: July 1, 2026 through December 31, 2027
Why this is historic: This is the first time Medicare has helped pay for medications prescribed solely for obesity. Previously, Medicare would only cover GLP-1 drugs when prescribed for type 2 diabetes (Ozempic, Mounjaro) or cardiovascular risk reduction — not for weight loss alone. This policy change reflects growing recognition that obesity is a treatable medical condition, not a lifestyle choice.
Scale of impact: Approximately 67 million Americans are enrolled in Medicare. CMS estimates that millions of beneficiaries may meet the eligibility criteria for the Bridge program. The program covers drugs made by both major manufacturers — Novo Nordisk (Wegovy) and Eli Lilly (Zepbound, Foundayo).
Eligibility: Exactly Who Qualifies
To access the Medicare GLP-1 Bridge, you must meet ALL of the following:
Insurance requirement: Enrolled in a Medicare Part D standalone prescription drug plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD) — including HMO, HMOPOS, and Local/Regional PPO plans — in calendar year 2026.
Clinical criteria (must meet at least one):
Tier 1 — BMI 35 or higher: No additional medical conditions required. If your BMI is 35+, you qualify on that basis alone.
Tier 2 — BMI 30 to 34.9: Must also have at least one of: heart failure, uncontrolled hypertension, or chronic kidney disease.
Tier 3 — BMI 27 to 29.9: Must also have at least one of: pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease.
How BMI is calculated: BMI = weight (kg) / height (m)^2. For reference: a 5'6" person weighing 217 lbs has a BMI of 35. A 5'10" person weighing 209 lbs has a BMI of 30. Use our reconstitution calculator page for BMI resources.
Who does NOT qualify: Medicare beneficiaries in Medicare Part A only, those without Part D coverage, those enrolled in Medicare Supplement (Medigap) plans without Part D, or those who do not meet the BMI and comorbidity criteria.
Covered Medications and How They Work
Wegovy (semaglutide) — Novo Nordisk - GLP-1 single agonist - Available as weekly injection and (new) daily oral tablet - Average weight loss: 16.9% at 68 weeks (STEP trials) - Proven cardiovascular benefit: 20% reduction in heart attacks and strokes (SELECT trial) - Most long-term safety data of any GLP-1 weight loss drug
Zepbound KwikPen (tirzepatide) — Eli Lilly - Dual GLP-1/GIP agonist - Weekly injection - Average weight loss: 22.5% at 72 weeks (SURMOUNT-1) — currently the most effective approved option - Particularly strong blood sugar control for those with pre-diabetes or diabetes risk
Foundayo (orforglipron) — Eli Lilly - Non-peptide oral GLP-1 agonist (daily pill) - FDA-approved in 2026 - The first oral small-molecule GLP-1 drug for weight loss - No injections required — a major convenience advantage
Important: Ozempic and Mounjaro are NOT covered under this program. These are the diabetes-indication versions of semaglutide and tirzepatide, respectively. Your provider must prescribe the weight-loss-specific products (Wegovy, Zepbound) for Bridge coverage.
*This content is for informational purposes only. Consult your healthcare provider and Medicare plan for specific coverage and eligibility details.*
Frequently Asked Questions
Who qualifies for the Medicare GLP-1 Bridge program?
You must meet three requirements: (1) Be 18 or older, (2) Be enrolled in a Medicare Part D standalone prescription drug plan (PDP) or Medicare Advantage plan with drug coverage (MA-PD) in 2026, and (3) Meet the clinical criteria — either a BMI of 35 or higher, a BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease, or a BMI of 27 or higher with pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease. Your prescribing provider will need to confirm you meet these criteria through the prior authorization process.
How much does the Medicare GLP-1 Bridge cost?
You pay a fixed $50 monthly copay for covered GLP-1 medications. Important caveats: this $50 copay does NOT count toward your Part D deductible or annual out-of-pocket cap, and Medicare Extra Help (Low-Income Subsidy) benefits cannot be applied to Bridge claims. The $50 is the same regardless of which covered medication you receive. For context, without the Bridge program, list prices for these drugs range from $550 to $1,300 per month.
Which drugs are covered under the Medicare GLP-1 Bridge?
Three products are covered when prescribed for weight reduction: Wegovy (semaglutide injection and tablets, made by Novo Nordisk), Zepbound KwikPen (tirzepatide, made by Eli Lilly), and Foundayo (orforglipron, made by Eli Lilly). Note that Ozempic and Mounjaro — the diabetes-indication versions of semaglutide and tirzepatide — are NOT covered under this program because they are approved for diabetes, not weight loss. Your provider must specifically prescribe the weight-loss indication products.
How do I enroll in the Medicare GLP-1 Bridge?
You do not need to separately enroll in the Bridge program. If you are eligible, your provider submits a prescription and prior authorization through the standard Medicare Part D process. CMS uses a single central processor to manage prior authorization, claims adjudication, and pharmacy payment. You can check your eligibility at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE. Your provider's office can also determine your eligibility and initiate the prior authorization.
Do GLP-1 drugs work for older adults?
Yes. A newly released study analyzing 358 adults aged 65 and older who participated in semaglutide (Wegovy) clinical trials confirmed that seniors lost an average of 15.5% of their body weight — nearly identical to the 15.6% average weight loss in younger adults. Side effect profiles were also similar. However, older adults should be particularly aware of the muscle loss concern: 25-40% of weight lost on GLP-1 drugs is lean mass, and sarcopenia (age-related muscle loss) is already a concern in older populations. Resistance training and high protein intake are especially important for seniors on GLP-1 therapy.
Sources
Related Compounds
About this article: Written by the PeptideMark Research Team. Published 2026-07-03. All factual claims are supported by cited sources where available. Editorial methodology · Medical disclaimer